Horizon Scanning of Medicines - Berichte und Fact Sheets

Decision Support Documents

Im Rahmen des Projekts Horizon Scanning in der Onkologie wurden bis Ende 2019 Assessments zu neuen Onkologika verfasst, für die bedeutende finanzielle und/oder therapeutische Konsequenzen vermutet werden und als Entscheidungsgrundlage für Kostenträger dienen.

Seit 2020 werden monatlich Fact Sheets zu allen neuen medikamentösen (Krebs)therapien verfasst, welche von der europäischen Zulassungsbehörde einen positiven Beschluss durch die Committee for Medicinal Products for Human Use (CHMP) erhalten haben.

Fact Sheets ab Januar 2020:
 

Fact Sheet Nr. 195 (September 2024) Neu!
Pembrolizumab (Keytruda®) for the treatment of adults with endometrial carcinoma

Fact Sheet Nr. 194 (September 2024) Neu!
Pembrolizumab (Keytruda®) with chemoradiotherapy (CRT) for the treatment of FIGO 2014 Stage III - IVA locally advanced cervical cancer

Fact Sheet Nr. 193 (September 2024) Neu!
Mirvetuximab soravtansine (Elahere®) for the treatment of adults with folate receptor-alpha (FR?) positive epithelial ovarian, fallopian tube and primary peritoneal cancer

Fact Sheet Nr. 192 (September 2024) Neu!
Serplulimab (Hetronifly®) with carboplatin and etoposide for the first?line treatment of extensive?stage small cell lung cancer (ES-SCLC)

Fact Sheet Nr. 191 (September 2024) Neu!
Daratumumab (Darzalex®) with bortezomib, lenalidomide and dexamethasone for the treatment of newly diagnosed multiple myeloma (MM)

Fact Sheet Nr. 190 (Juli 2024) 
Atezolizumab (Tecentriq®) as monotherapy for the first-line treatment of advanced NSCLC

Fact Sheet Nr. 189 (Juli 2024) 
Amivantamab (Rybrevant®) in combination with carboplatin and pemetrexed for the treatment of advanced non-small cell lung cancer (NSCLC)

Fact Sheet Nr. 188 (Juli 2024) 
Pembrolizumab (Keytruda®) with enfortumab vedotin (Padcev®) for the first-line treatment of unresectable or metastatic urothelial carcinoma

Fact Sheet Nr. 187 (Juli 2024) 
Encorafenib (Braftovi®) in combination with binimetinib (Mektovi®) for the treatment of advanced non-small cell lung cancer (NSCLC)

Fact Sheet Nr. 186 (Juli 2024) 
Zolbetuximab (Vyloy®) with chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2?negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma

Fact Sheet Nr. 185 (Juli 2024) 
Toripalimab (Loqtorzi®) with cisplatin and paclitaxel for the first-line treatment of unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (OSCC)

Fact Sheet Nr. 184 (Juli 2024) 
Toripalimab (Loqtorzi®) in combination with cisplatin and gemcitabine for the first-line treatment of recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma (NPC)

Fact Sheet Nr. 183 (Juni 2024) 
Epcoritamab (Tepkinly®) as monotherapy for the treatment of relapsed or refractory follicular lymphoma (FL) 

Fact Sheet Nr. 182 (Juni 2024) 
Durvalumab (Imfinzi®) in combination with carboplatin and paclitaxel for the first-line treatment of primary advanced or recurrent endometrial cancer (EC), followed by maintenance treatment durvalumab (Imfinzi®) as monotherapy in EC that is mismatch repair deficient (dMMR) or in combination with olaparib (Lynparza®) in EC that is mismatch repair proficient (pMMR)

Fact Sheet Nr. 181 (Juni 2024) 
Odronextamab (Ordspono®) as monotherapy for the treatment of relapsed or refractory follicular lymphoma (r/r FL) or diffuse large B?cell lymphoma (r/r DLBCL)

Fact Sheet Nr. 180 (Juni 2024) 
Erdafitinib (Balversa®) as monotherapy for the treatment of unresectable or metastatic urothelial carcinoma (UC)

Fact Sheet Nr. 179 (Mai 2024) 
Tislelizumab (Tevimbra®) monotherapy or in combination with chemotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) 

Fact Sheet Nr. 178 (Mai 2024) 
Osimertinib (Tagrisso®) with pemetrexed and platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer (NSCLC) 

Fact Sheet Nr. 177 (Mai 2024) 
Sugemalimab (Cejemly®) with platinum-based chemotherapy for the first?line treatment of metastatic non-small-cell lung cancer (NSCLC)

Fact Sheet Nr. 176 (April 2024)
Amivantamab (Rybrevant®) with carboplatin and pemetrexed for the first line treatment of advanced non-small cell lung cancer (NSCLC) with activating EGFR Exon 20 insertion mutations

Fact Sheet Nr. 175 (April 2024) 
Entrectinib (Rozlytrek®) as monotherapy for the treatment of solid tumours with a NTRK gene fusion

Fact Sheet Nr. 174 (April 2024)
Nivolumab (Opdivo®) in combination with cisplatin and gemcitabine for the first-line treatment of unresectable or metastatic urothelial carcinoma

Fact Sheet Nr. 173 (April 2024) 
Alectinib (Alecensa®) as adjuvant treatment following complete tumour resection for adult patients with ALK positive non-small cell lung cancer (NSCLC)

Fact Sheet Nr. 172 (April 2024) 
Capivasertib (Truqap®) with fulvestrant for the treatment ER-positive, HER2 negative locally advanced or metastatic breast cancer

Fact Sheet Nr. 171 (April 2024) 
Fruquintinib (Fruzaqla®) as monotherapy for the treatment of metastatic colorectal cancer (mCRC)

Fact Sheet Nr. 170 (März 2024) 
Enzalutamide (Xtandi®) as monotherapy or in combination with androgen deprivation therapy (ADT) for the treatment of high risk biochemical recurrent (BCR) non-metastatic hormone sensitive prostate cancer (nmHSPC)

Fact Sheet Nr. 169 (März 2024) 
Selpercatinib (Retsevmo®) as monotherapy for the treatment of advanced rearranged during transfection (RET) fusion-positive solid tumours

Fact Sheet Nr. 168 (März 2024) 
Irinotecan hydrochloride trihydrate (Onivyde® pegylated liposomal) in combination with oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV) for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas

Fact Sheet Nr. 167 (Februar 2024)
Pembrolizumab (Keytruda®) as pre- and post-operative treatment of resectable non small cell lung carcinoma (NSCLC)

Fact Sheet Nr. 166 (Februar 2024)
Ciltacabtagene autoleucel (Carvykti®) for the treatment of relapsed and refractory multiple myeloma (MM)

Fact Sheet Nr. 165 (Februar 2024)
Retifanlimab (Zynyz®) as monotherapy for the first line treatment of patients with metastatic or recurrent locally advanced Merkel cell carcinoma

Fact Sheet Nr. 164 (Februar 2024)
Tislelizumab (Tizveni®) in monotherapy or in combination with chemotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)

Fact Sheet Nr. 163 (Jänner 2024) Update
Selpercatinib (Retsevmo®) as monotherapy is indicated for the treatment of adults and adolescents with advanced RET fusion-positive thyroid cancer

Fact Sheet Nr. 162 (Jänner 2024) Update
Idecabtagene vicleucel (Abecma®) for the treatment of adult patients with relapsed and refractory multiple myeloma (MM) who have received at least two prior therapies

Fact Sheet Nr. 161 (November 2023) Update
Talazoparib (Talzenna®) in combination with enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC)

Fact Sheet Nr. 160 (November 2023) 
Momelotinib (Omjjara®) for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis (PMF), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis

Fact Sheet Nr. 159 (November 2023) 
Adagrasib (Krazati®) as monotherapy for the treatment of advanced non-small cell lung cancer (NSCLC) 

Fact Sheet Nr. 158 (November 2023) 
Pembrolizumab (Keytruda®) with gemcitabine and cisplatin for the first-line treatment of locally advanced unresectable or metastatic biliary tract carcinoma (BTC)

Fact Sheet Nr. 157 (November 2023) 
Avapritinib (Ayvakyt®) for the treatment of indolent systemic mastocytosis (ISM)

Fact Sheet Nr. 156 (Oktober 2023) 
Rucaparib (Rubraca®) as monotherapy for the maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer

Fact Sheet Nr. 155 (Oktober 2023) 
Pembrolizumab (Keytruda®) with fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction adenocarcinoma

Fact Sheet Nr. 154 (Oktober 2023) 
Dostarlimab (Jemperli®) with carboplatin and paclitaxel for the treatment of mismatch repair deficient (dMMR)/ microsatellite instability high (MSI-H) primary advanced or recurrent endometrial cancer (EC)

Fact Sheet Nr. 153 (Oktober 2023) 
Durvalumab (Imfinzi®) as monotherapy for the first line treatment of advanced or unresectable hepatocellular carcinoma (HCC)

Fact Sheet Nr. 152 (Oktober 2023) 
Elranatamab (Elrexfio®) as monotherapy for the treatment of relapsed and refractory multiple myeloma (MM)

Fact Sheet Nr. 151 (Oktober 2023) 
Zanubrutinib (Brukinsa®) with obinutuzumab for the treatment of refractory or relapsed follicular lymphoma (FL)

Fact Sheet Nr. 150 (September 2023) Update
Quizartinib (Vanflyta®) in combination with standard cytarabine and anthracycline induction and cytarabine consolidation chemotherapy, followed by single-agent maintenance therapy for patients with newly diagnosed acute myeloid leukaemia (AML)

Fact Sheet Nr. 149 (September 2023)
Melphalan flufenamide (Pepaxti®) in combination with dexamethasone for the treatment of multiple myeloma (MM)

Fact Sheet Nr. 148 (September 2023) Update
Pembrolizumab (Keytruda®) as monotherapy for the adjuvant treatment of non-small cell lung carcinoma (NSCLC)

Fact Sheet Nr. 147 (September 2023) Update
Trastuzumab deruxtecan (Enhertu®) as monotherapy for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumours have an activating HER2 (ERBB2) mutation

Fact Sheet Nr. 146 (September 2023) Update
Brentuximab vedotin (Adcetris®) in combination with doxorubicin, vinblastine and dacarbazine for previously untreated CD30+ Stage III or IV Hodgkin lymphoma

Fact Sheet Nr. 145 (August 2023) Update
Pembrolizumab (Keytruda®) with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction (GEJ) adenocarcinoma

Fact Sheet Nr. 144 (August 2023) Update
Nivolumab (Opdivo®) as monotherapy for the adjuvant treatment of Stage IIB or IIC melanoma, or melanoma with involvement of lymph nodes or metastatic disease

Fact Sheet Nr. 143 (August 2023) Update
Tislelizumab (Tevimbra®) as monotherapy for the treatment of unresectable, locally advanced, or metastatic oesophageal squamous cell carcinoma (OSCC)

Fact Sheet Nr. 142 (August 2023) 2. Update
Epcoritamab (Tepkinly®) as monotherapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Fact Sheet Nr. 141 (August 2023) Update
Talquetamab (Talvey®) for the treatment of adult patients with relapsed and refractory multiple myeloma (MM)

Fact Sheet Nr. 140 (August 2023) Update
Elacestrant (Orserdu®) monotherapy for the treatment of oestrogen receptor (ER)?positive, HER2-negative, locally advanced or metastatic breast cancer

Fact Sheet Nr. 139 (August 2023) Update
Cedazuridine/decitabine (Inaqovi®) for the treatment of newly diagnosed acute myeloid leukaemia (AML)

Fact Sheet Nr. 138  (August 2023) 2. Update
Crisantaspase (Enrylaze®) for the treatment of acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL)

Fact Sheet Nr. 137 (Juli 2023) Update
Sacituzumab govitecan (Trodelvy®) for the treatment of unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer

Fact Sheet Nr. 136 (Juli 2023) Update
Trifluridine / tipiracil (Lonsurf®, TAS-02) with bevacizumab for the treatment of metastatic colorectal cancer (CRC)

Fact Sheet Nr. 135 (Juli 2023) Update
Tremelimumab (Imjudo®) with durvalumab (Imfinzi®) and platinum-based chemotherapy for the first-line treatment of metastatic non-small cell lung cancer (NSCLC)

Fact Sheet Nr. 134 (Mai 2023) Update
Piflufolastat (18F) (Pylclari®) for the diagnosis of prostate cancer

Fact Sheet Nr. 133 (Mai 2023) Update
Nivolumab (Opdivo®) in combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable non-small cell lung cancer (NSCLC)

Fact Sheet Nr. 132 (Mai 2023) Update
Futibatinib (Lytgobi®) for the treatment of locally advanced or metastatic cholangiocarcinoma

Fact Sheet Nr. 131 (Mai 2023) 
Pirtobrutinib (JaypircaTM) as monotherapy for the treatment of relapsed or refractory (R/R) mantle cell lymphoma (MCL)

Fact Sheet Nr. 130 (Mai 2023) 2. Update
Glofitamab (Columvi®) as monotherapy for the treatment of relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

Fact Sheet Nr. 129 (April 2023) Update
Lisocabtagene maraleucel (Breyanzi®) bei DLBCL, HGBCL, PMBCL, FL3B

Fact Sheet Nr. 128 (April 2023) Update
Cemiplimab (Libtayo®) in combination with platinum-based chemotherapy for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)

Fact Sheet Nr. 127 (April 2023) 2. Update
Ivosidenib (Tibsovo®) monotherapy for the treatment of locally advanced or metastatic cholangiocarcinoma

Fact Sheet Nr. 126 (April 2023) Update
Ivosidenib (Tibsovo®, Tidhesco®) in combination with azacitidine for the treatment of newly diagnosed acute myeloid leukaemia (AML)

Fact Sheet Nr. 125 (April 2023) 2. Update
Niraparib/abiraterone acetate (Akeega®) for the treatment of metastatic castration-resistant prostate cancer (mCRPC)

Fact Sheet Nr. 124 (Februar 2023) 
Cipaglucosidase alfa (Pombiliti®) in combination with Miglustat for the treatment of adults with late-onset Pompe disease (acid alpha-glucosidase [GAA] deficiency)

Fact Sheet Nr. 123 (Februar 2023) Update
Darolutamide (Nubeqa®) in combination with docetaxel and androgen deprivation therapy (ADT) for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC)

Fact Sheet Nr. 122 (Februar 2023) 2. Update
Oportuzumab monatox (Vicineum®) for Bladder cancer

Fact Sheet Nr. 121 (Februar 2023) 2. Update
Nadofaragen Firadenovec (Adstiladrin®) for Bladder cancer

Fact Sheet Nr. 120 (Februar 2023) Update
Trastuzumab deruxtecan (Enhertu®) for HER2-low breast cancer

Fact Sheet Nr. 119 (Februar 2023) Update
Tremelimumab (Tremelimumab AstraZeneca®) + Durvalumab (Imfinzi®) + Chemotherapy for NSCLC

Fact Sheet Nr. 118 (Februar 2023) 2. Update
Tremelimumab (Imjudo®) + Durvalumab (Imfinzi®) for HCC

Fact Sheet Nr. 117 (Februar 2023) Update
Olaparib (Lynparza®) for mCRPC

Fact Sheet No. 116 (Dezember 2022) Update
Durvalumab (Imfinzi®) for Biliary tract cancer

Fact Sheet No. 115 (Dezember 2022) Update
Trastuzumab deruxtecan (Enhertu®) for Gastric or gastroesophageal junction (GEJ) adenocarcinoma

Fact Sheet Nr. 114 (November 2022) Update
Lutetium (177Lu) vipivotide tetraxetan (Pluvicto®) in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition for the treatment of metastatic castration-resistant prostate cancer (mCRPC)

Fact Sheet Nr. 113 (November 2022) Update
Cemiplimab (Libtayo®) as monotherapy for the treatment of recurrent or metastatic cervical cancer

Fact Sheet Nr. 112 (November 2022) Update
Zanubrutinib (Brukinsa®) as monotherapy for the treatment of adult patients with chronic lymphocytic leukaemia (CLL)

Fact Sheet Nr. 111 (Oktober 2022) Update
Axicabtagene ciloleucel (Yescarta®) for the treatment of patients with diffuse large B cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)

Fact Sheet Nr. 110 (Oktober 2022) Update
Zanubrutinib (Brukinsa®) as monotherapy for the treatment of marginal zone lymphoma (MZL)

Fact Sheet Nr. 109 (Oktober 2022) 2. Update
Loncastuximab tesirine (Zynlonta®) as monotherapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)

Fact Sheet Nr. 108 (August 2022) Update
Selpercatinib (Retsevmo®) as monotherapy for the treatment of adults and adolescents 12 years and older with advanced RET mutant medullary thyroid cancer (MTC)

Fact Sheet Nr. 107 (August 2022) Update
Teclistamab (Tecvayli®) as monotherapy for the treatment of patients with relapsed and refractory multiple myeloma (MM) who have received at least three prior therapies

Fact Sheet Nr. 106 (August 2022) Update
Autologous anti-CD19-transduced CD3+ cells (Tecartus®) for the treatment of adult patients 26 years of age and above with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL)

Fact Sheet Nr. 105 (August 2022) Update
Relatlimab/nivolumab (Opdualag®) for the first line treatment of advanced melanoma in adults and adolescents 12 years of age and older with tumour cell PD-L1 expression < 1%

Fact Sheet Nr. 104 (Juli 2022) Update
Olaparib (Lynparza®) as monotherapy or in combination with endocrine therapy for the adjuvant treatment of patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer

Fact Sheet Nr. 103 (Juli 2022) Update
Ibrutinib (Imbruvica®) in combination with venetoclax for the treatment of previously untreated chronic lymphocytic leukaemia (CLL)

Fact Sheet Nr. 102 (Juli 2022) Update
Trastuzumab deruxtecan (Enhertu®) as monotherapy for the treatment of unresectable or metastatic HER2 positive breast cancer

Fact Sheet Nr. 101 (Juli 2022) Update
Asciminib (Scemblix®) for the treatment of Philadelphia chromosome?positive (Ph+) chronic myeloid leukaemia (CML) in chronic phase (CP)

Fact Sheet Nr. 100 (Juli 2022) Update
Melphalan flufenamide (Pepaxti®) with dexamethasone for the treatment of multiple myeloma (MM)

Fact Sheet Nr. 99 (Juni 2022) Update
Pembrolizumab (Keytruda) as monotherapy for the adjuvant treatment of stage IIb IIc III melanoma

Fact Sheet Nr. 98 (Juni 2022) Update
Selinexor (Nexpovio®) in and dexamethasone for the treatment of multiple myeloma (MM)

Fact Sheet Nr. 97 (Mai 2022) Update
Axicabtagene ciloleucel (Yescarta®) Follicular lymphoma

Fact Sheet Nr. 96 (Mai 2022) Update
Atezolizumab (Tecentriq®) NSCLC

Fact Sheet Nr. 95 (Mai 2022) Update
Selpercatinib (Retsevmo®) NSCLC

Fact Sheet Nr. 94  (Mai 2022) Update
Pembrolizumab (Keytruda®) TNBC

Fact Sheet Nr. 93 (Mai 2022) Update
Capmatinib (Tabrecta®) NSCLC 

Fact Sheet Nr. 92 (Mai 2022) Update
Mosunetuzumab (Lunsumio®) Follicular lymphoma

Fact Sheet Nr. 91 (April 2022) Update
Pembrolizumab (Keytruda®) in combination with chemotherapy with or without bevacizumab for cervical cancer

Fact Sheet Nr. 90 (April 2022) Update
Pembrolizumab (Keytruda®) as monotherapy in adults with colorectal cancer

Fact Sheet Nr. 89 (April 2022) Update
Polatuzumab vedotin (Polivy®) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of B-cell lymphoma (DLBCL)

Fact Sheet Nr. 88 (April 2022) Update
Tisagenlecleucel (Kymriah®) for the treatment of follicular lymphoma (FL) after two or more lines of systemic therapy

Fact Sheet Nr. 87 (April 2022) Update
Cabozantinib (Cabometyx®) as monotherapy for the treatment of thyroid carcinoma (DTC)

Fact Sheet Nr. 86 (April 2022) Update
Ciltacabtagene autoleucel (Carvykti®) for the treatment of multiple myeloma (MM)

Fact Sheet No. 85 (März 2022) 2. Update
Enfortumab vedotin (Padcev®) as monotherapy for the treatment of patients with locally advanced or metastatic urothelial cancer

Fact Sheet Nr. 84 (März 2022) Update
Abemaciclib (Verzenios®) bei early breast cancer

Fact Sheet Nr. 83 (März 2022) Update
Nivolumab (Opdivo®) + chemotherapy bei OSCC

Fact Sheet Nr. 82 (März 2022) Update
Ipilimumab (Yervoy®) + Nivolumab (Opdivo®) bei OSCC

Fact Sheet Nr. 81 (März 2022) Update
Nivolumab (Opdivo®) bei MIUC

Fact Sheet Nr. 80 (März 2022)  2. Update
Relugolix (Orgovyx®) bei Prostate Cancer

Fact Sheet Nr. 79 (März 2022) 2. Update 
Tebentafusp (Kimmtrak®) bei Uveal melanoma

Fact Sheet Nr. 78 (Februar 2022) Update
Avapritinib (Ayvakyt®) for the treatment of advanced systemic mastocytosis (AdvSM)

Fact Sheet Nr. 77 (Februar 2022) Update
Lisocabtagene maraleucel (Breyanzi) for the treatment of relapsed or refractory DLBCL

Fact Sheet Nr. 76 (Jänner 2022) Update
Tegafur/gimeracil/oteracil (Teysuno®) for the treatment of metastatic colorectal cancer

Fact Sheet Nr. 75 (Jänner 2022) Update
Lorlatinib (Lorviqua®) as monotherapy for the treatment of anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC)

Fact Sheet Nr. 74 (Jänner 2022) Update
Pembrolizumab (Keytruda®) as monotherapy for the adjuvant treatment of renal cell carcinoma (RCC)

Fact Sheet Nr. 73 (Jänner 2022) Update
Tepotinib (Tepmetko®) as monotherapy for the treatment of patients with advanced non-small cell lung cancer (NSCLC)

Fact Sheet Nr. 72 (Jänner 2022) 
Enfortumab vedotin (Padcev®) as monotherapy for the treatment of patients with locally advanced or metastatic urothelial cancer

Fact Sheet Nr. 71 (November 2021) Update
Sotorasib (Lumykras®): Sotorasib (Lumykras®) as monotherapy for the treatment of advanced NSCLC with KRAS G12C mutation

Fact Sheet Nr. 70 (November 2021) Update
Sacituzumab govitecan (Trodelvy) as monotherapy for the treatment of patients with unresectable or metastatic triple-negative breast cancer (mTNBC)

Fact Sheet Nr. 69 (November 2021) Update
Amivantamab (Rybrevant) as monotherapy for the treatment of patients with advanced non-small cell lung cancer (NSCLC)

Fact Sheet Nr. 68 (November 2021) Update
Pembrolizumab (Keytruda) in combination with Lenvatinib (Kisplyx) for the treatment of advanced or recurrent endometrial carcinoma (EC)

Fact Sheet Nr. 67 (November 2021) Update
Pembrolizumab (Keytruda) in combination with Lenvatinib (Kisplyx) for the firstline treatment of advanced renal cell carcinoma (RCC)

Fact Sheet Nr. 66 (Juli 2022)
Degarelix (Firmagon®) as a neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone-dependent prostate cancer

Fact Sheet Nr. 65 (Juli 2022) 
Degarelix (Firmagon®) as a neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone-dependent prostate cancer

Fact Sheet Nr. 64 (Oktober 2021) Update
Pembrolizumab (Keytruda®) in combination with chemotherapy for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC)

Fact Sheet Nr. 63 (Oktober 2021) Update
Nivolumab (Opdivo®) in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the treatment of patients with HER2?negative advanced or metastatic gastric, gastro?oesophageal junction or oesophageal adenocarcinoma

Fact Sheet Nr. 62 (Oktober 2021) 2. Update
Ripretinib (Qinlock®) for the treatment of patients with advanced gastrointestinal stromal tumour (GIST)

Fact Sheet Nr. 61 (Oktober 2021) 2. Update
Pralsetinib (Gavreto®) as monotherapy for the treatment of patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC)

Fact Sheet Nr. 60 (Oktober 2021) Update
Zanubrutinib (Brukinsa®) as monotherapy for the treatment of patients with waldenström’s macroglobulinaemia (WM)

Fact Sheet Nr. 59 (Juli 2021) Update
Adjuvant nivolumab (Opdivo®) as monotherapy for the treatment of patients with oesophageal (OC) or gastro-oesophageal junction cancer (GEJC)

Fact Sheet Nr. 58 (Juli 2021) Update
Tafasitamab (Minjuvi®; Monjuvi®) for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Fact Sheet Nr. 57 (Juli 2021) Update
Idecabtagene vicleucel (Abecma®) for the treatment of patients with relapsed and refractory multiple myeloma (MM)

Fact Sheet Nr. 56 (Mai 2021) Update
Daratumumab (Darzalex®) in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of newly diagnosed systemic light chain (AL) amyloidosis

Fact Sheet Nr. 55 (Mai 2021) Update
Daratumumab (Darzalex®) in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma (MM)

Fact Sheet Nr. 54 (Mai 2021) Update
Pembrolizumab (Keytruda®) in combination with platinum and fluoropyrimidine based chemotherapyfor the treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus

Fact Sheet Nr. 53 (Mai 2021) Update
Cemiplimab (Libtayo®) as monotherapy for the treatment of locally advanced or metastatic basal cell carcinoma (laBCC or mBCC)

Fact Sheet Nr. 52 (Mai 2021) Update
Cemiplimab (Libtayo®) as monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC)

Fact Sheet Nr. 51 (Mai 2021) Update 
Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) for the treatment of patients with mismatch repair deficient (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer

Fact Sheet Nr. 50 (April 2021) Update
Nivolumab (Opdivo®) in combination with ipilimumab for the first-line treatment of patients with unresectable malignant pleural mesothelioma

Fact Sheet Nr. 49 (April 2021) Update
Venetoclax (Venclyxto®) in combination with a hypomethylating agent for the treatment of patients with newly diagnosed acute myeloid leukaemia (AML)

Fact Sheet Nr. 48 (April 2021) Update
Osimertinib (Tagrisso®) as monotherapy for the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC)

Fact Sheet Nr. 47 (April 2021) Update
Azacitidine (Onureg®) for the maintenance treatment of patients with acute myeloid leukaemia (AML)

Fact Sheet Nr. 46 (März 2021) Update
Enzalutamide (Xtandi^®) for the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT)

Fact Sheet Nr. 45 (März 2021) Update
Atezolizumab (Tecentriq^®) as monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC)

Fact Sheet Nr. 44 (März 2021) Update
Duvelisib (Copiktra^®) for the treatment of patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) and refractory follicular lymphoma (FL)

Fact Sheet Nr. 43 (Februar 2021) Update
Isatuximab (Sarclisa^®) in combination with carfilzomib and dexamethasone for the treatment of patients with multiple myeloma (MM)

Fact Sheet Nr. 42 (Februar 2021) Update
Nivolumab (Opdivo^®) in combination with cabozantinib (Cabometyx^®) for the first-line treatment of patients with advanced renal cell carcinoma (RCC)

Fact Sheet Nr. 41 (Februar 2021) 2. Update
Dostarlimab (Jemperli^®) for the treatment of patients with recurrent or advanced mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer (EC)

Fact Sheet Nr. 40 (Jänner 2021) Update
Pemigatinib (Pemazyre®) for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement

Fact Sheet Nr. 39 (Jänner 2021) 2. Update
Selinexor (Nexpovio®) in combination with dexamethasone for the treatment of relapsed and refractory multiple myeloma (MM)

Fact Sheet Nr. 38 (Jänner 2021) Update
Pembrolizumab (Keytruda®) is indicated for the treatment of adult and paediatric patients with relapsed or refractory classical Hodgkin lymphoma (cHL)

Fact Sheet Nr. 37 (Dezember 2020) Update
Tucatinib (Tukysa®) with trastuzumab and capecitabine for the treatment of HER2-positive locally advanced or metastatic breast cancer

Fact Sheet Nr. 36 (Dezember 2020) Update
Selpercatinib (Retsevmo®) for the treatment of RET-fusion positive NSCLC, RET-fusion positive thyroid cancer and RET-mutant medullary-thyroid cancer

Fact Sheet Nr. 35 (Dezember 2020) 2. Update
Moxetumomab pasudotox (Lumoxiti®) for the treatment of patients with relapsed or refractory hairy cell leukaemia (HCL)

Fact Sheet Nr. 34 (Dezember 2020) Update
Pembrolizumab (Keytruda®) as monotherapy for the first-line treatment of MSI H or dMMR colorectal cancer

Fact Sheet Nr. 33 (Dezember 2020) 2. Update
Fedratinib (Inrebic®) for the treatment of primary and secondary myelofibrosis

Fact Sheet Nr. 32 (Dezember 2020) Update
Trastuzumab deruxtecan (Enhertu®) in patients with previously treated HER2-positive breast cancer

Fact Sheet Nr. 31 (Dezember 2020) Update
Avelumab (Bavencio®) as monotherapy for the first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma

Fact Sheet Nr. 30 (November 2020) Update
A fixed-dose combination of pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) for the treatment of early and metastatic breast cancer

Fact Sheet Nr. 29 (November 2020) Update
Carfilzomib (Kyprolis®) with daratumumab and dexamethasone for the treatment of adult patients with multiple myeloma (MM)

Fact Sheet Nr. 28 (November  2020) 2. Update
Tagraxofusp (Elzonris^®) in blastic plasmacytoid dendritic-cell neoplasm (BPDCN)

Fact Sheet Nr. 27 (Oktober 2020) Update
Autologous anti-CD19-transduced CD3+ cells (Tecartus®) for the treatment of relapsed or refractory mantle cell lymphoma (MCL)

Fact Sheet Nr. 26 (Oktober 2020) Update
Nivolumab (Opdivo®) as monotherapy for the treatment of unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OESCC)

Fact Sheet Nr. 25 (Oktober 2020) Update
Blinatumomab (Blincyto®) for the treatment of patients with Philadelphia chromosome positive B-precursor acute lymphoblastic leukaemia (ALL)

Fact Sheet Nr. 24 (September 2020) Update
Olaparib (Lynparza®) plus bevacizumab as first-line maintenance treatment in patients with ovarian cancer

Fact Sheet Nr. 23 (September 2020) Update
Olaparib (Lynparza®) for metastatic castration-resistant prostate cancer (mCRPC)

Fact Sheet Nr. 22 (September 2020) Update
Niraparib (Zejula®) in patients with newly diagnosed advanced ovarian cancer

Fact Sheet Nr. 21 (September 2020) Update
Nivolumab (Opdivo®) plus ipilimumab (Yervoy®) and chemotherapy as first-line treatment for metastatic non-small cell lung cancer (NSCLC)

Fact Sheet Nr. 20 (September 2020) Update
Atezolizumab (Tecentriq®) plus bevacizumab for the treatment of advanced or unresectable hepatocellular carcinoma (HCC)

Fact Sheet No. 19 (Juli 2020) Update
Ibrutinib (Imbruvica®) as a single agent or in combination with rituximab or obinutuzumab  for the treatment of previously untreated chronic lymphocytic leukaemia (CLL)

Fact Sheet Nr. 18 (Juli 2020) Update
Durvalumab (Imfinzi®) in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC)

Fact Sheet Nr. 17 (Juli 2020) 3. Update
Belantamab mafodotin (Blenrep®) as monotherapy for the treatment of relapsed or refractory multiple myeloma (MM)

Fact Sheet Nr. 16 (Juli 2020) 2. Update
Avapritinib (Ayvakyt®) for the treatment of gastrointestinal stromal tumours (GIST)

Fact Sheet Nr. 15 (Juli 2020) Update
Acalabrutinib (Calquence®) for the treatment of chronic lymphocytic leukaemia (CLL)

Fact Sheet Nr. 14 (ad April 2020)
Carmustine (Carmustine Obvius®) as conditioning treatment before transplantation in patients with Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphomas (NHL)

Fact Sheet Nr. 13 (Mai 2020) Update
Entrectinib (Rozlytrek®) for the treatment of patients whose solid tumours have a NTRK gene fusion, or patients with ROS1-positive advanced NSCLC

Fact Sheet Nr. 12 (Mai 2020) Update
Alpelisib (Piqray®) plus fulvestrant for PIK3CA-mutated, hormone receptor–positive advanced breast cancer

Fact Sheet Nr. 11 (Mai 2020) 
Maintenance olaparib (Lynparza®) for the treatment of patients with germline BRCA-mutated metastatic pancreatic cancer

Fact Sheet Nr. 10 (April 2020) 
Glasdegib (Daurismo^®) with low-dose cytarabine (LDAC) in patients with newly diagnosed acute myeloid leukaemia (AML)

Fact Sheet Nr. 9 (April 2020) 
Daratumumab (Darzalex®) in a new pharmaceutical form associated with a new strength and a new route of administration for the treatment of multiple myeloma

Fact Sheet Nr. 8 (April 2020) Update
Cabazitaxel Accord for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with a docetaxel containing regimen

Fact Sheet Nr. 7 (April 2020) 
Encorafenib (Braftovi®) in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation

Fact Sheet Nr. 6 (März 2020) 
Isatuximab (Sarclisa®) plus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (MM)

Fact Sheet Nr. 5 (März 2020) 
Brentuximab vedotin (Adcetris®) with chemotherapy for CD30-positive peripheral T-cell lymphoma (PTCL)

Fact Sheet Nr. 4 (Februar 2020) 
Brigatinib (Alunbrig®) in ALK-positive non–small-cell lung cancer (NSCLC)

Fact Sheet Nr. 3 (Januar 2020)
Rituximab (MabThera®) for the treatment of paediatric patients with previously untreated advanced stage CD20 positive DLBCL, BL, BAL, or BLL

Fact Sheet Nr. 2 (Januar 2020) 
Darolutamide (Nubeqa®) in nonmetastatic, castration-resistant prostate cancer (nmCRPC)

Fact Sheet Nr. 1 (Januar 2020) 
Venetoclax (Venclyxto®) and obinutuzumab in patients with chronic lymphocytic leukaemia (CLL) and coexisting conditions

 

Publikationsreihe von Oktober 2009 bis Dezember 2019 (in Englischer Sprache):

DSD HSO No 91
Pembrolizumab (Keytruda®) as first-line therapy for PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (NSCLC)

DSD HSO No. 90
Enzalutamide (Xtandi®) in addition to standard first-line therapy in men with metastatic hormone-sensitive prostate cancer (mHSPC)

DSD HSO Nr. 90
Enzalutamid (Xtandi®) in Kombination mit Standard-Erstlinientherapie bei Patienten mit metastasiertem hormonsensitivem Prostatakarzinom (mHSPC)

DSD HSO Nr. 89
Brentuximab vedotin (Adcetris®) plus Chemotherapie für die Behandlung von PatientInnen mit CD30-positiven, peripheren T-Zell Lymphom (PTCLs)

DSD HSO Nr. 88
Darolutamide für die Behandlung von Patienten mit nichtmetastasiertem, kastrationsresitentem Prostatakarzinom

DSD HSO Nr. 87
Atezolizumab (Tecentriq®) und Nab-Paclitaxel (Abraxane®) für die Behandlung von Patientinnen mit fortgeschrittenem, triple-negativem Mammakarzinom (aTNBC)

DSD HSO Nr. 86
Olaparib (Lynparza®) für die Erstlinien-Erhaltungstherapie von Patientinnen mit neu diagnostiziertem, fortgeschrittenem Ovarialkarzinom

DSD HSO Nr. 85
Ibrutinib (Imbruvica®) in Kombination mit Rituximab für die Behandlung von PatientInnen mit Makroglobulinämie Waldenström

DSD HSO Nr. 84
Enzalutamide (Xtandi®) für die Behandlung von Patienten mit nichtmetastasiertem, kastrationsresistentem Prostatakarzinom

DSD HSO Nr. 83
Pembrolizumab (Keytruda®) in Kombination mit Chemotherapie für die Behandlung von PatientInnen mit nicht-kleinzelligem Lungenkarzinom (NSCLC)

DSD HSO Nr. 82
Nivolumab (Opdivo®) in Kombination mit Ipilimumab (Yervoy®) für die Erstlinientherapie von PatientInnen mit fortgeschrittenem Nierenzellkarzinom

DSD HSO Nr. 81
Daratumumab (Darzalex®) in Kombination mit Bortezomib, Melphalan und Prednison für die Erstlinienbehandlung von PatientInnen mit multiplem Myelom

DSD HSO Nr. 80
Osimertinib (Tagrisso®) für die Erstlinientherapie zur Behandlung von PatientInnen mit nicht-kleinzelligem Lungenkarzinom und EGFR-Mutation

DSD HSO Nr. 79
Rituximab (MabThera®) für die Behandlung des Mantelzellkarzinoms nach autologer Stammzelltransplantation

DSD HSO Nr. 78
Abemaciclib (Verzenio®) in Kombination mit einem nicht-steroidalen Aromatasehemmer als Initialtherapie bei fortgeschrittenem Mammakarzinom (ABC) 

DSD HSO Nr. 77
Alectinib als Monotherapie zur Erstlinienbehandlung von Erwachsenen mit ALK-positivem, fortgeschrittenem, nicht-kleinzelligem Lungenkarzinom (NSCLC)

DSD HSO Nr. 76
Durvalumab (Imfinzi™) für die Behandlung von PatientInnen mit Stadium-III nicht-kleinzelligem Lungenkarzinom nach vorheriger Radiochemotherapie

DSD HSO Nr. 75
Nivolumab (Opdivo®) für die Behandlung von PatientInnen mit metastasiertem Kolorektalkarzinom mit defizientem DNA Mismatch-Reparatur-System (dMMR) oder hoher Mikrosatelliteninstabilität (MSI-H)

DSD HSO Nr. 74
Midostaurin in Kombination mit Standardchemotherapie zur Behandlung von PatientInnen mit FLT3-positiver akuter myeloischer Leukämie (AML)

DSD HSO Nr. 73
Regorafenib als Monotherapie zur Behandlung von Erwachsenen mit hepatozellulärem Karzinom (HCC) nach vorangegangener Therapie mit Sorafenib

DSD HSO Nr. 72
Abemaciclib (Verzenio®) für die Behandlung von PatientInnen mit HR-positivem, HER2-negativem fortgeschrittenem Mammakarzinom

DSD HSO Nr. 71
Olaparib (Lynparza®) für die Behandlung von PatientInnen mit metastasiertem Mammakarzinom mit BRCA-Mutation

DSD HSO Nr. 70
Pembrolizumab (Keytruda®) für die Zweitlinientherapie bei PatientInnen mit fortgeschrittenem Urothelkarzinom (UC)

DSD HSO Nr. 69
Ceritinib (Zykadia®) für die Erstlinientherapie von PatientInnen mit fortgeschrittenem ALK-positivem nicht-kleinzelligem Lungenkarzinom

DSD HSO Nr. 68
Atezolizumab (Tecentriq®) für vorbehandelte PatientInnen mit nicht-kleinzelligem Lungenkarzinom

DSD HSO Nr. 67
Ipilimumab (Yervoy®) als adjuvante Therapie für Hochrisiko-PatientInnen mit kutanem Stadium-III-Melanom

DSD HSO Nr. 66
Neratinib für die Behandlung von PatientInnen mit HER2-positivem Mammakarzinom nach adjuvanter Trastuzumab-basierter Therapie

DSD HSO Nr. 65
Ribociclib in Kombination mit Letrozole für die Erstlinientherapie des hormonrezeptor-positivem, human-epidermalem Wachstumsfaktor-Rezeptor 2 negativen rezidivierenden oder metastasierten Brustkrebs

DSD HSO Nr. 64
Palbociclib (Ibrance®) in Kombination mit Fulvestrant für die Behandlung von Hormonrezeptor positivem und HER2 negativem, fortgeschrittenem oder metastasiertem Mammakarzinoms

DSD HSO Nr. 63
Ixazomib (Ninlaro®) in Kombination mit Lenalidomid und Dexamethason für die Behandlung von PatientInnen mit Multiplem Myelom (MM)

DSD HSO Nr. 62
Venetoclax (Venclexta^TM) für die Therapie von relapsierter oder refraktärer chronischer lymphatischer Leukämie (CLL) mit Chromosom 17p-Deletion

DSD HSO Nr. 61
Atezolizumab (Tecentriq^TM) für die Behandlung von lokal fortgeschrittenem und metastasiertem Urothelkarzinom 

DSD HSO Nr. 60
Obinutuzumab (Gazyvaro®) in Kombination mit Bendamustine bei erwachsenen PatientInnen mit rezidiviertem/refraktärem follikulärem Lymphom (FL)

DSD HSO Nr. 59
Afatinib (Giotrif®) für PatientInnen mit refraktärem nicht-kleinzelligem Lungenkrebs nach der Behandlung mit erlotinib/gefitinib und afatinib Monotherapie

DSD HSO Nr. 58
Pembrolizumab (Keytruda®) bei vorbehandeltem fortgeschrittenem nicht-kleinzelligem Lungenkarzinom

DSD HSO Nr. 57
Ofatumumab (Arzerra®) als Erhaltungstherapie bei PatientInnen mit rezidivierter chronischer lymphatischer Leukämie

DSD HSO Nr. 56
Bevacizumab (Avastin®) in Kombination mit Standard-Chemotherapie für die Erstlinienbehandlung des Ovarialkarzinoms

DSD HSO Nr. 55
Pembrolizumab (Keytruda®) für die Behandlung des fortgeschrittenen Melanoms

DSD HSO Nr. 54
Ramucirumab in Kombination mit Paclitaxel als Zweitlinientherapie bei erwachsenen PatientInnen mit fortgeschrittenem Magenkarzinom oder Karzinom des gastroösophagealen Übergangs

DSD HSO Nr. 53
Nivolumab (Nivolumab BMS®) als Zweitlinientherapie des metastasierenden, nicht-kleinzelligen Lungenkarzinoms mit plattenepithelialer Histologie 

DSD HSO Nr. 52
Carfilzomib (Kyprolis®) für die Behandlung von PatientInnen mit rezidiviertem multiplem Myelom nach ein bis drei vorangegangenen Therapien

DSD HSO Nr. 51
Bevacizumab (Avastin®) in Kombination mit Chemotherapie als Zweitlinienbehandlung für Patientinnen mit HER2-negativem, lokal rezidivierendem oder metastasierendem Brustkrebs bei Krankheitsprogression nach Erstlinienbehandlung mit Bevacizumab und Chemotherapie

DSD HSO Nr. 50
Nivolumab (Opdivo®) als Monotherapie für die Erstlinienbehandlung von inoperablen oder metastasierten Melanomen

DSD HSO Nr. 49
Idelalisib (Zydelig®) in Kombination mit Rituximab für die Behandlung von PatientInnen mit relapsierter chronisch lymphatischer Leukämie

DSD HSO Nr. 48
Bevacizumab (Avastin®) für platinum-resistentes, rezidivierendes epitheliales Eierstock-, Eileiter oder primäres Peritonealkarzinom

DSD HSO Nr. 47
Ibrutinib (Imbruvica®) for relapsierte oder refraktäre chronisch lymphatische Leukämie

DSD HSO Nr. 46
Bevacizumab (Avastin®) zur Erhaltungstherapie nach Krankheitsprogression mit Bevacizumab-beinhaltender Erstlinientherapie bei metastasierendem kolorektalem Karzinom

DSD HSO Nr. 45
Obinutuzumab (Gazyva®) als Erstlinientherapie bei chronisch lymphatischer Leukämie (CLL)

DSD HSO Nr. 44
Radium-223 dichlorid (Xofigo®) für die Behandlung von Patienten mit kastrationsresistentem Prostatakrebs, symptomatischen Knochenmetastasen ohne bekannte viszerale Metastasen

DSD HSO Nr. 43
Nab-Paclitaxel (Abraxane®) als Erstlinientherapie bei metastasiertem Adenokarzinoms des Pankreas

DSD HSO Nr. 42
Dabrafenib (Tafinlar ®) für unbehandelte PatientInnen mit BRAF-Mutation-positivem fortgeschrittenem (Stadium III) oder metastasiertem (Stadium IV) Melanom

DSD HSO Nr. 41
Afatinib (Giotrif®) für EGFR-TKI unbehandelte erwachsene PatientInnen mit lokal fortgeschrittenem oder metastasiertem nicht-kleinzelligen Lungenkrebs (NSCLC) mit aktivierenden EGFR-Mutation(en)

DSD HSO Nr. 40
Regorafenib (Stivarga®) für mehrfach vorbehandelte PatientInnen mit metastasierendem kolorektalem Karzinom

DSD HSO Nr. 39
Pomalidomid (Pomalyst®) für die ? Drittlinientherapie von PatientInnen mit rezidiviertem und refraktärem multiplem Myelom

DSD HSO Nr. 38
Aflibercept (Zaltrap®) in Kombination mit FOLFIRI für die Zweitlinientherapie des metastasierenden kolorektalen Karzinoms 

DSD HSO Nr. 37
Enzalutamide (Xtandi®) für Patienten mit metastasiertem, kastrationsrefraktärem Prostatakarzinom nach Chemotherapie mit Docetaxel

DSD HSO Nr. 36
Trastuzumab emtansine (KadcylaTM) für vorbehandelte PatientInnen mit HER2 positivem fortgeschrittenem/metastasiertem Mammakarzinom

DSD HSO Nr. 35
Crizotinib (Xalkori®) für die Behandlung von Anaplastische-Lymphom-Kinase (ALK)-positivem, fortgeschrittenem nicht kleinzelligem Bronchialkarzinom 

DSD HSO Nr. 34
Trametinib für fortgeschrittenes oder metastasiertes BRAF V600 Mutation-positives Melanom

DSD HSO Nr. 33
Lenalidomid (Revlimid®) für die Erstlinientherapie von nichttransplantationsfähigen PatientInnen mit multiplem Myelom

DSD HSO Nr. 32
Everolimus (Afinitor® or Votubia®) in Kombination mit Exemestan zur Therapie des Hormonrezeptor-positiven, HER2/neu-negativen, fortgeschrittenen Mammakarzinoms bei postmenopausalen Frauen, nach Rezidiv oder Progression nach Letrozol oder Anastrozol

DSD HSO Nr. 31
Pertuzumab (Omnitarg/Perjeta®) für die Erstlinientherapie von metastasiertem, HER2 positivem Brustkrebs

DSD HSO Nr. 30
Ipilimumab (Yervoy®) für die Erstlinientherapie von PatientInnen mit fortgeschrittenem/metastasiertem Melanom

DSD HSO Nr. 29
Bortezomib (Velcade®) als Konsolidierungs- oder Erhaltungstherapie nach autologer Stammzelltransplantation bei Patienten mit neu diagnostiziertem Multiplem Myelom

DSD HSO Nr. 28 
Lenalidomide (Revlimid®) für die Therapie von transfusionsabhängiger Anämie bei geringem/mittlerem (Stufe 1) Risiko von myelodysplastischen Syndromen mit partieller Deletion des Chromosoms Nummer 5 („5q-Deletion“)

DSD HSO Nr. 27
Bevacizumab (Avastin®) in Kombination mit Chemotherapie bei vorbehandeltem metastasiertem Brustkrebs

DSD HSO Nr. 26
Brentuximab (Adcetris®) zur Behandlung von rezidiviertem Hodgkin Lymphom (HL) oder rezidiviertem systemischen anaplastischen großzelligen Lymphom (sALCL)

DSD HSO Nr. 25
Romidepsin (Istodax®) zur Behandlung von Patienten mit refraktärem oder rezidiviertem peripherem T-Zell Lymphom (PTCL) nach einer systemischen Chemotherapie  

DSD HSO Nr. 24
Everolimus (Afinitor®) für die Behandlung von fortgeschrittenen, progressiv verlaufenden, neuroendokrinen Tumoren pankreatischen Ursprungs (pNET)

DSD HSO Nr. 23
Vemurafenib für die Behandlung von fortgeschrittenen/metastasierten Melanomen mit BRAF V600E Mutationen

DSD HSO Nr. 22
Erlotinib (Tarceva®) für die Erstlinienbehandlung von PatientInnen mit lokal fortgeschrittenem/metastasiertem nicht-kleinzelligem Lungenkarzinom mit aktivierenden EGFR Mutationen

DSD HSO Nr. 21
Axitinib (AG013736, Inlyta®) als Zweitlinientherapie zur Behandlung von metastasiertem Nierenzellkarzinom

DSD HSO Nr. 20
Abiraterone acetate (Zytiga ^TM) für die Zweilinientherapie von metastasiertem, kastrationsrefraktärem Prostatakarzinom

DSD HSO Nr. 19
S-1 (TeysunoTM) als Erstlinientherapie bei Patienten mit fortgeschrittenem nicht kleinzelligen Lungenkarzinom

DSD HSO Nr. 18
Eribulin (Halaven®) als “third or late-line” Monotherapie bei fortgeschrittenem/metastasiertem Brustkrebs

DSD HSO Nr. 17
Dasatinib (Sprycel®) als Erstlinienbehandlung der Philadelphia-Chromosom positiven chronischen myeloischen Leukämie in der chronischen Phase

DSD HSO Nr. 16
Zweitlinienchemotherapie mit Cabazitaxel (Jevtana®) für die Behandlung von metastasiertem kastrationsrefraktärem Prostatakarzinom

DSD HSO Nr. 15
Nilotinib (Tasigna®) als Erstlinienbehandlung der Philadelphia-Chromosom positiven chronischen myeloischen Leukämie in der chronischen Phase

DSD HSO Nr. 14
Ipilimumab für vorbehandelte PatientInnen mit fortgeschrittenem/metastasiertem Melanom

DSD HSO Nr. 13
Pazopanib (Votrient®) zur Behandlung von lokal fortgeschrittenem und/oder metastasiertem Nierenzellkarzinom

DSD HSO Nr. 12
Trastuzumab (Herceptin®) in Kombination mit Standardchemotherapie als Erstlinientherapie von metastasiertem Magenkarzinom

DSD HSO Nr. 11
Panitumumab (Vectibix®) als Erstlinientherapie zur Behandlung von metastasiertem Kolorektalkarzinom

DSD HSO Nr. 11/ 1. Update 2011
Panitumumab (Vectibix®) als Erstlinientherapie zur Behandlung von WT KRAS metastasiertem Kolorektalkarzinom

DSD HSO Nr. 10
Bendamustin (Ribomustin®/Treanda®/ Levact®) zur Behandlung von indolentem Non-Hodgkin Lymphom (NHL), Chronisch Lymphatischer Leukämie (CLL) und Multiplem Myelom

DSD HSO Nr. 9
Lapatinib ditosylate (Tyverb/Tykerb®) als Erstlinientherapie zur Behandlung von fortgeschrittenem/metastasiertem Mamma-Karzinom

DSD HSO Nr. 8 
Plerixafor (Mozobil®) für autologe Stammzelltransplantation für PatientInnen mit Lymphomen und Multiplen Myelomen

DSD HSO Nr. 7
Trabectedin (Yondelis®) als Zweitlinientherapie zur Behandlung von rezidiviertem platinsensitivem Ovarialkarzinom.

DSD HSO Nr. 6
Gefitinib (Iressa®) als Erstlinientherapie zur Behandlung von nicht-kleinzelligem Lungenkarzinom.

DSD HSO Nr. 6/ 1. Update 2011
Gefitinib (Iressa®) als Erstlinientherapie für nicht-kleinzelliges Lungenkarzinom – 1. Update 2011

DSD HSO Nr. 5
Ibritumomab tiuxetan (Zevalin®) als Konsolidierungstherapie nach erster Remission bei follikulärem Lymphom

DSD HSO Nr. 4
Rituximab (Rituxan® / MabThera®) für die Therapie chronisch lymphatischer Leukämien

DSD HSO Nr. 4/ 1. Update 2011
Rituximab (Rituxan®/MabThera®) für die Therapie chronisch lymphatischer Leukämien – 1. Update 2011

DSD HSO Nr. 3
Everolimus (Afinitor®) zur Behandlung von fortgeschrittenem/metastasiertem Nierenzellkarzinom

DSD HSO Nr. 2
Cetuximab (Erbitux®) bei nicht-kleinzelligem Lungenkarzinom mit EGF-Rezeptor

DSD HSO Nr. 1
Azacitidine (Vidaza®) für die Therapie von myelodysplastischen Syndromen

Kontakt: Nicole Grössmann